Hikma boosts Egyptian growth with acquisition
FTSE 250 pharmaceutical group HIkma is to buy the Egyptian Company for Pharmaceuticals & Chemical Industries as it strengthens its position in a rapidly growing market.
FTSE 250 pharmaceutical group HIkma is to buy the Egyptian Company for Pharmaceuticals & Chemical Industries as it strengthens its position in a rapidly growing market.
It is to pay EGP142.4m - around $22.2m - to buy the firm from a consortium of shareholders.
Hikma's Chief Executive, Said Darwazah, said that since his company entered the Egyptian market in 2007, it had rapidly grown its presence in a country that had excellent growth opportunities.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This acquisition will further accelerate that growth, expanding our product portfolio and adding additional manufacturing capacity and technologies," he said.
The company quoted IMS Health figures, which showed Egypts private retail market was valued at around $2.3bn and grew by 10.6% in the twelve months to June 2012.
Hikma Egypt said it was the seventeenth largest pharmaceutical manufacturer in Egypt, with an estimated market share of 1.6%.
-
Lifetime ISA reform: Retirement option could be scrapped in overhaulA consultation on a product replacing the Lifetime ISA is set to be launched this year, and the option to use it to save for retirement is expected to be axed in the shake-up
-
HMRC stamp duty crackdown sees probes of property deals jump 88% – what to watch out forFrom bogus stamp duty refund claims to misleading the taxman about who owns a property, HMRC is increasing its scrutiny of stamp duty land tax reporting. Here’s how.
